Top 10: Diagnostics Companies

The global clinical diagnostics industry is valued at approximately US$110bn and is expected to grow towards US$169bn by 2030, according to Grand View Research.

The sector covers in vitro diagnostics (IVD), point-of-care (POC) testing, molecular diagnostics, genomics and imaging diagnostics.

Healthcare Digital explores the top 10 biggest diagnostics companies in the world, ranked by market capitalisation.

10. Philips

Market cap: US$25.81bn
CEO: Roy Jakobs
HQ: Amsterdam, the Netherlands

Philips owns a portfolio of diagnostic products and solutions including MRI and CT systems for high-quality diagnostic imaging.

It also offers diagnostic and clinical informatics that integrate diagnostics across radiology, cardiology, oncology and digital pathology.

This involves the company's advanced visualisation and AI, with precision imaging solutions for radiology departments.

This helps patients to receive the right treatment faster and allows healthcare professionals to make confident diagnostic decisions.

9. GE Healthcare

Market cap: US$37.53bn
CEO: Peter J. Arduini
HQ: Chicago, Illinois, US

GE Healthcare provides contrast media and radiopharmaceutical imaging agents for medical imaging examinations, helping medical professionals in more than 130 countries.

These solutions help diagnose, treat and monitor patients across all major disease pathways including neurology, cardiology and oncology.

Its contrast media products help improve the visibility of specific organs, blood vessels or tissues during imaging procedures, while its radiopharmaceutical imaging agents visualise and measure biological processes in the body.

8. Agilent Technologies

Market cap: US$37.86bn
CEO: Padraig McDonnell
HQ: California, US

Agilent offers pathology solutions as part of its commitment to fighting cancer.

It provides a range of tissue diagnostic solutions, companion diagnostic assays and an end-to-end digital pathology workflow for labs and partners.

Its solutions help labs enhance diagnostic conditions through accurate testing and appropriate technology application, reducing the time from biopsy to diagnosis.

7. Shenzhen Mindray Bio-Medical Electronics

Market cap: US$38.5bn
CEO: Hao Wu
HQ: Shenzhen, China

Mindray's diagnostics portfolio covers IVD solutions, including haematology analysers, clinical chemistry and chemiluminescence.

It also provides medical imaging systems, such as high-performance ultrasound and digital radiography.

Mindray offers automated solutions to optimise workflow and maximise lab efficiency, helping labs meet the increasing efficiency demands while delivering accurate results.

6. Siemens Healthineers

Market cap: US$41.2bn
CEO: Dr Bernd Montag
HQ: Erlangen, Germany

Siemens Healthineers offers laboratory diagnostic systems, including automation for routine work, which helps staff focus on solving problems and building relationships.

It focuses on connecting patients with the care they need, through specialised systems and analysers.

Bernd Montag, CEO of Siemens Healthineers, says on LinkedIn: "Together with our customers and partners, we're making real progress by connecting capabilities in imaging, laboratory diagnostics, image-guided therapy and AI – across modalities and settings – to create a more coherent approach to identifying risk and managing it more proactively."

5. Becton, Dickinson and Company (BD)

Market cap: US$55bn
CEO: Tom Polen
HQ: New Jersey, US

BD offers a portfolio of diagnostic solutions to help elevate the patient experience and optimise efficiencies.

Its solutions cover all stages of the diagnostic process, including sample collection, transportation, processing and analysis.

It offers a spectrum of blood culture media solutions for detecting organism recovery from adult and paediatric patients.

BD also produces viral systems designed to transport viruses and plasma at room temperature.

4. Danaher Corporation

Market cap: US$161.7bn
CEO: Rainer M. Blair
HQ: Washington D.C., US

Danaher's diagnostic companies aim to create tools and technologies that help healthcare providers achieve the goal of precision medicine.

Its technologies improve the quality of data collection and allows medical professionals to observe, quantify and track biomarkers to better understand and treat disease.

It uses generative and predictive AI, data integration and knowledge generation to enable digital collaboration for medical staff and patients.

3. Thermo Fisher Scientific

Market cap: US$182.66bn
CEO: Marc Casper
HQ: Waltham, Massachusetts, US

Thermo Fisher Scientific offers specialty diagnostics, laboratory and biotechnology services.

It provides instruments, solutions, services and support to meet the needs of modern diagnostic laboratories.

This includes biomarker testing, allergy and autoimmune testing, immunosuppressant drug monitoring, clinical chemistry and genetic analysis.

2. Abbott Laboratories

Market cap: US$217.87bn
CEO: Robert B. Ford
HQ: Chicago, Illinois, US

Abbott Laboratories produces core laboratory diagnostic solutions, aiming towards better healthcare performance at hospitals, laboratories and clinics across the world.

It creates molecular testing solutions and point-of-care diagnostics for key health areas, designed to bring speed and accuracy to medical professionals.

Abbott also focuses on toxicology diagnostics, providing reliable, innovative and value-focused drug and alcohol abuse screening products and lab services to its customers.

1. Roche

Market cap: US$281.6bn
CEO: Thomas Schinecker
HQ: Basel, Switzerland

Roche Diagnostics is a division of Roche, focusing on advancing diagnostic solutions to support healthcare professionals in making critical decisions for their patients' health.

It offers an IVD testing portfolio, combined with clinical decision support, consultancy, digital diagnostics, disease management, laboratory automation and software solutions.

Thomas Schinecker, CEO of Roche, writes on LinkedIn: "Living longer matters even more when people can live those years in better health, with diseases detected earlier, treated more precisely and monitored more effectively.

"The future of healthcare will not be shaped by tests or treatments alone, but by integrated solutions across the patient journey.

"This is where Roche's unique combination of Diagnostics and Pharma becomes especially powerful."